Virtual colonoscopy and contrast developer E-Z-EM of Lake Success, NY, has inked a deal with Berlex Laboratories, a U.S. subsidiary of Berlin-based Schering, for Berlex’s x-ray diagnostic contrast agent Ultravist (iopromide).
Under the terms of the agreement, E-Z-EM will promote Ultravist to a targeted list of CT facilities in the U.S. and Berlex will pay E-Z-EM a co-promotion royalty on sales to its target customers. The five-year agreement is effective as of this month, the companies said.
By AuntMinnie.com staff writersJuly 15, 2003
Related Reading
E-Z-EM to close New York and Puerto Rico operations, June 2, 2003
E-Z-EM, 3CPM sign agreement, April 17, 2003
E-Z-EM shows sales growth in Q3, April 15, 2003
E-Z-EM and JPC ink multiyear deal, April 10, 2003
E-Z-EM closes deal with MAGNET, March 19, 2003
Copyright © 2003 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
